Boston Scientific (BSX) says its ION and TAXUS Liberte Paclitaxel-Eluting Coronary Stent Systems...

|About: Boston Scientific Corporation (BSX)|By:, SA News Editor

Boston Scientific (BSX) says its ION and TAXUS Liberte Paclitaxel-Eluting Coronary Stent Systems have received FDA approval for use in patients experiencing a heart attack. They are the only drug-eluting stent systems in the country with an approved indication to treat heart attack patients. Shares +1.4% AH.